Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Combining for companion biomarkers
September 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

RESEARCH TRIANGLE PARK, N.C.—August saw the beginning of a partnership agreement between Cloud Pharmaceuticals Inc. and Genomeon LLC that will enable Cloud to offer companion biomarkers as part of its drug development process. Though no financial details were disclosed, Cloud Pharmaceuticals gains access to Genomeon’s microsatellite technology to scan next-generation sequencing data for novel drug targets and companion biomarkers.
 
Dr. Harold Ray “Skip” Garner, chief science officer and co-founder of Genomeon, noted in a press release, “The backlog of actionable markers and targets for cancers and neurological diseases, and the ability to quickly identify new ones from emerging next-gen sequencing data, is ideally matched to Cloud Pharmaceuticals’ rapid drug development process. Clients will benefit from this new paradigm in drug and diagnostic development.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.